MAIA Biotechnology (MAIA) Expected to Announce Quarterly Earnings on Friday

MAIA Biotechnology (NYSEAMERICAN:MAIA) is anticipated to release its Q4 2025 results before the market opens on Friday, March 20th. Analysts expect MAIA Biotechnology to post earnings of ($0.13) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 20, 2026 at 4:00 PM ET.

MAIA Biotechnology Price Performance

Shares of NYSEAMERICAN MAIA opened at $1.57 on Friday. The business has a 50-day moving average of $1.95 and a 200-day moving average of $1.58. The stock has a market capitalization of $60.70 million, a price-to-earnings ratio of -2.15 and a beta of -0.04. MAIA Biotechnology has a fifty-two week low of $0.87 and a fifty-two week high of $3.19.

Insider Activity at MAIA Biotechnology

In related news, Director Steven M. Chaouki purchased 40,849 shares of the firm’s stock in a transaction on Monday, December 22nd. The stock was purchased at an average cost of $1.22 per share, for a total transaction of $49,835.78. Following the completion of the purchase, the director directly owned 151,873 shares in the company, valued at $185,285.06. This trade represents a 36.79% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ngar Yee Louie purchased 81,699 shares of the stock in a transaction on Monday, December 22nd. The shares were bought at an average cost of $1.22 per share, for a total transaction of $99,672.78. Following the transaction, the director directly owned 1,248,888 shares in the company, valued at approximately $1,523,643.36. The trade was a 7.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders purchased 179,737 shares of company stock valued at $219,279. Insiders own 32.32% of the company’s stock.

Hedge Funds Weigh In On MAIA Biotechnology

Several hedge funds and other institutional investors have recently made changes to their positions in MAIA. Jane Street Group LLC bought a new stake in MAIA Biotechnology during the fourth quarter worth $120,000. Geode Capital Management LLC grew its position in shares of MAIA Biotechnology by 9.5% in the 4th quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock valued at $454,000 after acquiring an additional 25,684 shares during the period. Finally, Marshall Wace LLP bought a new stake in shares of MAIA Biotechnology in the 2nd quarter valued at about $29,000. 5.65% of the stock is owned by institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.